B7‐33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction–Related Adverse Cardiac Remodeling in MiceTeja Devarakonda(Virginia Commonwealth University), Fadi N. Salloum(Virginia Commonwealth University)Journal of the American Heart AssociationApril 16, 202010.1161/jaha.119.015748Cited by 20SaveCiteExport RISWatch citationsRelated PapersChronic treatment with serelaxin mitigates adverse remodeling in a murine model of ischemic heart failure and modulates bioactive sphingolipid signaling|Scientific Reports|2022|8